Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CCTC up 167%. Can I do another pick now,cargo?
CCTC is a nice set up for a bottom reversal
CCTC is a nice set up for a bottom reversal
Bottom fishing has been BERRY BERRY good to me. LOL
AXTG really does look good here. CLAYTRADER!?? Could you do a chart on it? Thanks
Actually, I have done well. The only problem sometimes is that you get a headfake at the 10DMA, you get in, and it fades. But that can happen with any trading strategy. It also rules out trading a V bottom bounce because it takes two weeks to see the 10DMA get that low. But, again, it often protects me.
CTIC could go out of business if the FDA gives them a bad decision on Thursday
Charts are absolutely worthless in a case like CTIC is in. IMO
When you have the very real possibility that CTIC can go out of business if they get a negative decision in the next day or two, how in the world will a "technical breakout" or "holding support" tell yoy anything?
What a heading on this article!
Cell Therapeutics’ Last Hope for Survival, Dashed
By Lisa LaMotta Feb 08, 2010 2:20 pm
Shares plunge on news that its only promising drug could get rejected.
Cell Therapeutics (CTIC) took a dive into the penny-stock territory on Monday after documents were released by the FDA about the company’s non-Hodgkin’s lymphoma drug.
The documents are a preview of what’s to come on Wednesday when the Oncologic Drugs Advisory Committee, a panel of experts that advises the FDA, meets to decide whether they should recommend the investigational therapy to the FDA for approval -- the outcome doesn’t look good.
The Cell Therapeutics story isn't a pretty one. The approval of pixantrone, to be called Pixuvri if approved, is the company’s last hope for survival. The drug is meant to treat lymphoma patients who haven't had success with prior treatments. The cornerstones of the therapy are anthracyclines, which are potent cancer-cell-killing agents that are often used in first-line treatment, but can cause heart damage when used repeatedly. Pixantrone looks to capitalize on the benefits of the anthracyclines without the drawbacks. The company said at the JPMorgan Healthcare Conference in San Francisco earlier this year that it expects to reach about 10,000 patients with the drug and compared its price point to that of Cephalon’s (CEPH) Treanda, which garners $40,000 per patient annually. The company is expected to face an FDA decision on approval on April 23.
"The upcoming ODAC meeting is a very important milestone in the NDA review process and we look forward to discussing the efficacy and safety data for pixantrone with the members of the panel and the FDA review team," said James Bianco, chief executive of Cell Therapeutics. "As there are no other drugs currently approved in this setting, we believe that pixantrone would fulfill a significant unmet medical need for patients with relapsed/refractory aggressive NHL."
The stock has been all over the place during the course of the last 52 weeks with a range of $0.05 to $2.23 (it’s been trading at a range between 0.9298 and 0.5299 today). The company’s finances have also been all over the place, as its cash levels dwindled to just weeks’ worth at one point last year. Its biggest problem is that it doesn’t have any products on the market generating revenues and doesn’t have anything (other than pixantrone) that's even within throwing distance of the FDA approval process.
Yet, the death knell has all but tolled for this little company, which has been basing its livelihood on a late-stage study of only 140 patients. The study violates the Special Protocol Assessment, an agreement made with the FDA that defines the parameters of the clinical trial, because the company ceased enrollment of the study early -- not sticking to the 320 patients that were supposed to be enrolled -- and decided to analyze trial data sooner than expected.
The advisory panel questioned the "the level of evidence necessary to draw conclusions from this Phase III study and the reliability of these conclusions," and whether "substantial hematologic and cardiac toxicity" were safety factors that the agency should be concerned about when considering this drug for approval.
The data from Cell Therapeutics shows that almost twice as many patients had serious cardiac events while on pixantrone than those on other chemotherapy drugs, 9% to 4.5%, respectively. The data presented in June also showed that pixantrone had some other severe side effects including the depletion of white blood cells.
Meanwhile, documents provided by the company to the FDA panel state that the drug is both safe and effective based on the trials that have been done thus far.
I watch alot of possible bottom busters.Looking for 10 Day Moving Average breakouts on 3-5 times normal volume before I get into any bottom bouncer possibility.
The data on CTIC's drug is much better than the initial reports. All is not over for CTIC
How much cash on hand do they have?
Why Winning Streaks End
04:08 PM Monday February 08, 2010
By Rosabeth Moss Kanter
That crashing sound you hear is not an accident caused by sudden acceleration of your hybrid car; it is the continuing toppling of idols, such as hybrid car companies, off their pedestals. Listen hard, lest you be next.
Toyota, the world's leading auto company, faces a series of product problems causing a $2 billion recall, an investigation by the National Highway Traffic Safety Administration, and a galling loss of face for a company from face-conscious Japan. This follows its first annual financial loss in 50 years, with profitability regained partly through cost-cutting.
Sayonara for a while to Toyota's reputation for quality control and invincibility. But in Dearborn, Michigan, there are no smug smiles. Ford announced that it is also fixing electronic brakes in its hybrid cars after a damaging review by Consumer Reports and more generalized concerns about electronics in cars.
The noise continues. In banking, the latest jackhammer blow to any remaining pedestal pieces is a civil fraud lawsuit against former Bank of America CEO Kenneth Lewis. Okay, bankers might not be saints, but the saintly are crashing, too. Ten U.S. missionaries were arrested in Haiti on charges of abducting children, apparently admitting that they had neglected to secure all the necessary permissions, and with hints that some of the "orphans" had living parents. Do some people who feel they are doing good think that they can bend a few inconvenient rules to do it?
And if these weren't enough reminders about fallen idols for one week, the Super Bowl did not feature my favorite team, the New England Patriots, whose period of NFL dominance snapped this fall among hints of eroding focus and discipline.
All too often, long periods of continued success are undermined not by the competition but by self-inflicted wounds. I uncovered common patterns in business, sports, leadership, and life in research for my book Confidence: How Winning Streaks & Losing Streaks Begin & End.
Winners become sinners when confidence turns into complacency and arrogance. They over-estimate their own invincibility and under-value mundane disciplines. Whenever someone feels on top over a long period of time, they are tempted to neglect the very fundamentals that helped them succeed in the first place. They might even start to feel that the rules don't apply to them.
Success means that people or teams or organizations survive long enough to need maintenance, repairs, and reinvestment. Winners undergo natural aging processes, as people get older, slow down, leave. Facilities, tools, and bags of tricks get older, deteriorate, and run down. Newcomers might get less rigorous training while long-timers forget what they learned. As momentum runs down, people and buildings begin to look run down. Neglect takes on tangible physical manifestations, such as out-of-shape bodies or broken windows. Add to this the pressures in a recession to cut costs and defer expenditures.
Erosion begins by removing a process or discipline. Let's defer those roof repairs for another year... Let's cut out one practice; we already have so many... Let's save time by eliminating the weekly team meeting... The Chernobyl nuclear plant disaster was said to be caused by engineers neglecting small portions of routine safety checks because they had done so before, and nothing had happened. Oops.
Whether you head a company, lead a good cause, or coach your children's soccer teams, your job is to root out complacency. Remember to:
# Keep up the essential disciplines every single day, not skipping a single one.
# Keep checking everything carefully.
# Repair, renew, relearn, and reinvest regularly.
# Don't rejoice in others' misery, because you could be next.
# Thank anyone who points out flaws. Listen to disgruntled customers or disaffected constituencies.
# Treat even small setbacks as occasions for redoubled efforts.
"Winning is great, but sometimes it takes a loss to get you motivated again. It humbles you down to reality," said a high school athlete in my research. That youth speaks truth! Although he might not be old enough to drive a Toyota, he is headed in the right direction.
Missed it, WANG. Ride it until it bucks you off!
Hey, I rent stocks, basically. I really do not care about long-term. I look for an idea --sometimes they are stocks moving up already, sometimes they are at lows--and I play them for news or momentum. This UTRM is just interesting in that it is so low and just basic clicking on news shows that in Dec. they introduced their product. Maybe they were wrong or too early to do that, and the stock is down because they were too early. But my bet (a bet) is that with news on sales, a contract, a partnership, whatever, and this stock heads up. If they have made mistakes with their online orders, so be it. When they fix it, that is am improvement. Maybe I trade more than you so I do not get all caught up in a frenzy. Can I ask you something, Southergal? Do you really have shares and you want them to go down in value even more? I mean, I have been so po'ed at a company before that I camped out on their Yahooo board blasting them, but it was after I sold out. Whatever. To better returns!!
UP 27% on a down day in the markets. HZHI treating langlui nicely. Congratulations
Uh OH--TImber